SonoProbe®

High Intensity Contact Ultrasound Interstitial Medical Device

The Sonoprobe Medical Device

SonoProbe is a diagnostic and therapeutic treatment probe percutaneously introduced in a tumor under local anaesthesia. Slightly larger than a biospy needle, the SonoProbe is composed of dozens of miniaturized ultrasound transducers that are able to emit high intensity ultrasound waves for therapy.

Treatments with the SonoProbe are continuously monitored and controlled by software that interfaces with an MR imaging system, performs treatment simulations, and executes treatments with real-time temperature feedback control.

In the figure below, the color code corresponds to heating of brain tissue around the probe. On this figure, the probe is artificially represented for clarity, as the probe is nearly invisible on the MR images.

This innovation and development are currently in pre-clinical testing, which will soon allow for an application in humans for the treatment of brain tumors.  

 

 

mixte

  • unnamed-2
    unnamed-3

     
  • News CarThera

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.

    03.07.2017
    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.